Transdermal administration of NPC-22 or placebo once daily for 7 days

2 trials

Sponsors

Miyoshi Katsunori, Katsunori Miyoshi

Conditions

Sialorrhea

Phase 1

Repeated dose study of NPC-22

Active, not recruitingJPRN-jRCT2031210169

Miyoshi KatsunoriSialorrhea

Start: 2021-07-03Target: 16Updated: 2026-06-29

Phase 2

Phase I/II study of NPC-22

Active, not recruitingJPRN-jRCT2031210612

Katsunori MiyoshiSialorrhea

Start: 2022-03-20Target: 15Updated: 2026-06-29